Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Operating Activities:
Net loss	$ (25,545)	$ (14,955)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization [note 3]	117	114
Stock-based compensation [note 7[c], note 7[e] and note 7[f]]	5,120	2,742
Accrued interest on 2023 SVB convertible term loan [note 6]		624
Amortization of 2024 SVB convertible term loan transaction costs [note 6]	28
Accretion of discount on modification of debt		322
Change in fair value of contingent consideration [note 4 and note 5]	188	109
Changes in operating assets and liabilities:
Grant receivable		111
Prepaid expenses and other assets	592	61
Accounts payable	(732)	(68)
Accrued liabilities other	646	266
Accrued clinical liabilities	893	1,428
Accrued compensation	(1,464)	(962)
Lease obligation [note 8]		(1)
Net cash used in operating activities	(20,157)	(10,209)
Financing Activities:
Taxes paid related to net share settlement of equity awards		(114)
Net cash provided by financing activities	41,222	55,957
Investing Activities:
Purchase of marketable securities	(4,260)	(46,568)
Maturities of marketable securities	22,316
Net cash provided by (used in) investing activities	18,056	(46,568)
Net increase/(decrease) in cash, cash equivalents and restricted cash	39,121	(820)
Cash, cash equivalents and restricted cash at beginning of the period	12,773	15,596
Cash, cash equivalents and restricted cash at end of the period	51,894	14,776
February 2024 Registered Direct Offering [Member]
Financing Activities:
Proceeds from registered direct offering, net of issuance costs		$ 56,071
June 2025 Public Offering [Member]
Financing Activities:
Proceeds from public offering, net of issuance costs	$ 41,222